Stay informed with the latest litigation news. Explore now

Jazz Pharmaceuticals Ireland competitive analysis

Latest publications and patents of Jazz Pharmaceuticals Ireland New

Explore the latest publications and patents granted to Jazz Pharmaceuticals Ireland, showcasing their recent innovations and technological advancements.

Last updated on: Sep 6, 2025
Publication NumberPublication DateTitleLegal Status

Get instant update for new patents of Jazz Pharmaceuticals Ireland

Dec 20, 2023Solvate Form Of (R)-2-Amino-3-Phenylpropyl CarbamateGranted And Under Opposition
Nov 9, 2022Formulations Of (RGranted And Under Opposition
Jul 20, 2022Treatment Of CataplexyGranted And Under Opposition
Dec 11, 2019Administration Of Gamma Hydroxybutyrate With Monocarboxylate TransportersRevoked
Nov 15, 2017Administration Of Gamma Hydroxybutyrate With Monocarboxylate TransportersRevoked

Explore Jazz Pharmaceuticals Ireland's recently opposed patents, revealing key competitive challenges and strategic patent disputes in the industry. Track oppositions filed by competitors to understand technology battlegrounds and assess potential risks.

Last updated on: Sep 11, 2025
Patent NumberGrant DateTitleTotal Oppositions
Dec 20, 2023Solvate Form Of (R)-2-Amino-3-Phenylpropyl Carbamate1
Nov 9, 2022Formulations Of (R1
Jul 20, 2022Treatment Of Cataplexy1
Dec 11, 2019Administration Of Gamma Hydroxybutyrate With Monocarboxylate Transporters4
Nov 15, 2017Administration Of Gamma Hydroxybutyrate With Monocarboxylate Transporters3

Latest PTAB cases involving Jazz Pharmaceuticals Ireland New

Discover the latest PTAB cases involving Jazz Pharmaceuticals Ireland, highlighting their recent legal challenges and patent disputes.

Last updated on: Sep 12, 2025
Proceeding NumberFiling DatePetitionerRespondentStatus

Get alerts for PTAB Cases involving Jazz Pharmaceuticals Ireland

IPR2016-00738Mar 10, 2016RANBAXYJAZZ PHARMACEUTICALS IRELANDInstitution Denied

Top competitors of Jazz Pharmaceuticals Ireland

Top competitors of Jazz Pharmaceuticals Ireland based on patent oppositions.